Johnson & Johnson's First Oral Psoriasis Drug Icotyde Secures FDA Approval Based on Phase 3 Success
Arrival of a Game Changer: Approval of an Oral IL-23 Inhibitor
Johnson & Johnson's psoriasis therapy Icotyde (generic name: icotrokina/icotrokinra) has received final approval from the U.S. Food and Drug Administration (FDA), poised to reshape the market. The drug is the first oral peptide that targets and inhibits the interleukin‑23 receptor (IL‑23R), representing an innovative therapy that could shift the current injection‑centric treatment paradigm. Previously, patients with moderate‑to‑severe psoriasis had to visit clinics every two weeks or every few months for injections to achieve optimal efficacy; now a once‑daily tablet can deliver comparable therapeutic benefit. This convenience is expected to dramatically improve patients’ quality of life and ultimately maximize treatment adherence.
Overwhelming Phase 3 Clinical Data Demonstrate Efficacy
The FDA approval is underpinned by the ICONIC Phase 3 program, which robustly established the drug’s clinical value and safety. In the pivotal ICONIC‑LEAD study, 50 % of patients receiving icotrokina achieved a Psoriasis Area and Severity Index 90 (PASI 90) at week 16, versus 4 % in the placebo arm, demonstrating overwhelming efficacy. Efficacy continued to improve, with approximately 65 % of patients reaching PASI 90 by week 24. Moreover, in the ICONIC‑TOTAL trial that enrolled patients with difficult‑to‑treat scalp and nail psoriasis, the overall Investigator’s Global Assessment (IGA 0/1) endpoint was fully met, dispelling market‑access concerns.
Reshaping the $20 B Psoriasis Market Landscape
The global psoriasis therapeutic market exceeds $20 billion annually and is currently dominated by injectable biologics such as AbbVie’s Skyrizi. Icotyde’s approval is expected to directly challenge Bristol‑Myers Squibb’s (BMS) oral agent Sotyktu (generic name: deucravacitinib), which inhibits tyrosine kinase 2 (TYK2). Because the IL‑23 pathway targeted by Icotyde is a key upstream driver of psoriasis pathogenesis, it holds superior efficacy potential. The hybrid advantage of injectable‑level skin clearance combined with oral convenience is likely to intensify competition for market share.
Financial Win‑Win from the Co‑Development Partnership
The approval creates a substantial financial inflection point not only for Johnson & Johnson but also for co‑developer Protagonist Therapeutics. The companies entered a co‑development agreement in 2017; as of early 2025, Protagonist has already secured $337.5 million in upfront payments and milestone fees. An additional up‑to $630 million in sales milestones remains contingent on commercial success, positioning the company for significant valuation uplift. Furthermore, Protagonist will receive royalty rights ranging from a minimum of 6 % to a maximum of 10 % of global annual net sales, generating a robust cash‑flow stream.
This FDA approval of Icotyde marks the first oral IL‑23 inhibitor in a psoriasis market exceeding $20 billion annually, providing short‑term momentum that could accelerate the biotech industry’s shift from injectable to oral therapies. Investors should focus on the drug’s potential for rapid market‑share expansion and long‑term financial impact, given its superior Phase 3 PASI 90 data relative to the existing oral competitor, BMS’s Sotyktu. Co‑developer Protagonist Therapeutics, which has already secured $337.5 million, stands to increase its financial independence further with up to $630 million in future sales milestones and royalty rates of 6 %–10 %. Researchers and industry professionals should also consider that the design‑platform technology enabling an oral peptide to target the high‑molecular‑weight IL‑23 receptor could be applied to other immune‑mediated diseases, driving subsequent pipeline development.
Source: FDA Drug Approvals (rss)
http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs